Onal, C. Et Al. 2023. Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study. Strahlentherapie und Onkologie , vol.199, no.5 , 456-464.

Onal, C., Oymak, E., Guler, O. C., TİLKİ, B., Yavas, G., HÜRMÜZ, P., ... Yavas, C.(2023). Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study. Strahlentherapie und Onkologie , vol.199, no.5, 456-464.

Onal, Cem Et Al. "Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study," Strahlentherapie und Onkologie , vol.199, no.5, 456-464, 2023

Onal, Cem Et Al. "Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study." Strahlentherapie und Onkologie , vol.199, no.5, pp.456-464, 2023

Onal, C. Et Al. (2023) . "Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study." Strahlentherapie und Onkologie , vol.199, no.5, pp.456-464.

@article{article, author={Cem Onal Et Al. }, title={Stereotactic body radiotherapy and tyrosine kinase inhibitors in patients with oligometastatic renal cell carcinoma: a multi-institutional study}, journal={Strahlentherapie und Onkologie}, year=2023, pages={456-464} }